Anjarium Biosciences


Anjarium Biosciences AG is at the forefront of the emerging field of exosome-based therapeutics, with a focus on advancing its pipeline of targeted RNA medicines for cancer and rare monogenic diseases. Anjarium’s proprietary Hybridosome™ technology creates unmatched advantages in the realm of engineering exosomes -- opening the door to harnessing the naturally occurring communication between cells for RNAi, mRNA and gene editing-based therapeutics. Building on this versatile platform, we are pursuing a RNA therapeutics pipeline and are seeking further collaborations in additional diseases in which patients would benefit the most from RNA therapeutic options.